BioAge Labs (BIOA) vs Cartesian Therapeutics (RNAC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cartesian Therapeutics (RNAC) has outperformed BioAge Labs (BIOA) over the past year, losing 15.2% versus a loss of 50.5%. BioAge Labs is the larger company by market cap ($196.7 million vs $187.3 million), about 1.1 times the size. BioAge Labs converts more of its revenue into profit, with a net margin of -896.1% versus -4658.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIOA | RNAC |
|---|---|---|
| Share price | $4.28 | $6.14 |
| Market cap | $196.67M | $187.29M |
| 1-day change | -9.13% | +4.24% |
| YTD return | -67.65% | -14.84% |
| 1-year return | -50.52% | -15.19% |
| 5-year return | — | -92.94% |
| EPS (TTM) | $-2.56 | $-4.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $8.99M | $2.80M |
| Revenue growth (YoY) | — | -92.81% |
| Net income (latest FY) | $-80.61M | $-130.30M |
| Operating margin | -1031.46% | -5127.10% |
| Net margin | -896.11% | -4658.63% |
| 52-week high | $25.96 | $11.00 |
| 52-week low | $4.24 | $5.60 |
| Distance from 52-week high | -83.51% | -44.18% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +572.43% | +448.37% |
| Average volume | 740.06K | 139.65K |
| Shares outstanding | 45.95M | 30.50M |
| Employees | 60 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RNAC has outperformed BIOA by 35.3 percentage points over the past year.
- BioAge Labs is more profitable, keeping -896.1 cents of every revenue dollar as net income versus -4658.6 cents for Cartesian Therapeutics.
About BioAge Labs
BIOA stock →BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
About Cartesian Therapeutics
RNAC stock →Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
BIOA vs RNAC FAQ
Which is bigger, BioAge Labs or Cartesian Therapeutics?
BioAge Labs (BIOA) is larger, with a market capitalization of $196.67M compared with $187.29M for Cartesian Therapeutics (RNAC).
Which stock has performed better over the past year, BIOA or RNAC?
RNAC returned -15.19% over the past 12 months, compared with -50.52% for BIOA (price return, excluding dividends). Past performance does not predict future results.
Are BioAge Labs and Cartesian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.